Navigation Links
The Melanoma Research Alliance Foundation supports CNIO research

A consortium led by the Spanish National Cancer Research Centre's researcher Mara S. Soengas −Programme Director of the Centres Molecular Pathology Programme and Leader of the CNIO Melanoma Group− has been selected to receive funding from the Melanoma Research Alliance (MRA), the most important private international melanoma research foundation, in order to advance research in melanoma; this type of skin tumour represents one of oncology's biggest challenges due to its high incidence and malignancy.

The main goals of the project, which has been awarded $900,000, are aimed at generating molecular tools and validating new compounds that block the formation of lymphatic vessels, one of the main routes that cancer cells use to conquer new organs and generate metastasis.

To this end, Soengas will coordinate the work of world-leading researchers in the fields of oncology, pathology, dermatology, medical chemistry or tumour spectrometry, from institutions such as the Swiss Federal Institute of Technology in Munich, the National Institute of Health and Medical Research in Paris, Ludwig Maximilian University in Munich or the Weill Cornell Medical College in New York.

According to Soengas, for decades, the prognosis for patients with melanoma has been largely defined by the presence or absence of tumour cells in the lymph nodes adjacent to the tumour. "Up until now, however, we have not been able to detect the activation of the lymphatic vessels (lymphangiogenesis) before melanoma cells disseminate through the organism", she adds.

This project seeks to provide a solution to this problem, in addition to validating efficient anti-metastatic drugs. "We have generated the first melanoma models to visualise the activation of lymphangiogenesis in vivo. These models will also allow us to carry out pharmacological studies to determine the efficiency and stability of new anti-metastatic therapies", says CNIO researcher.

Furthermore, researchers will study several drugs under clinical development, as well as nanoparticles discovered by CNIO that have led to the creation of Bioncotech Therapeutics, a CNIO spin-off dedicated to anti-cancer therapies.

With the current round of funding of $9.6 million, this award brings the total awarded by MRA in its 6-year history to almost $48 million, destined to promoting multidisciplinary research to improve the treatment of patients with melanoma.


Contact: Nuria Noriega
Centro Nacional de Investigaciones Oncologicas (CNIO)

Related medicine news :

1. Surgery Rates Rising for Non-Melanoma Skin Cancer: Study
2. Moffitt Cancer Center researchers working at frontiers of melanoma research
3. Women More Likely to Survive Melanoma Than Men: Study
4. Scientists Map Melanomas Genome
5. Two-Drug Combo May Be Safe for Melanoma Treatment
6. Melanoma a Big Threat to Older Men
7. Fish shed light on human melanoma
8. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
9. New Melanoma Drug May Extend Survival
10. New Guidelines Issued for Biopsy Use in Melanoma Patients
11. Melanoma-promoting gene discovered
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today ... owner, Somu now offers travelers, value and care based Travel Services, including exclusive ... as well as, cabin upgrades and special amenities such as, shore excursions, discounted ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer ... classically-influenced trailer titles work with any font, giving users limitless opportunities to stylize ...
(Date:11/25/2015)... ... 2015 , ... The holiday season is jam-packed with family ... of attendees is of the utmost importance. Whether you are cooking at home ... recipes a try this holiday season. , Turkey Croquettes ,     Ingredients: ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior ... (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies ... the opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like ... , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. ... OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... WILMINGTON, N.C. , Nov. 25, 2015 /PRNewswire/ ... announces the planned investment of at least $15.8 ... in Wilmington, NC . The ... services capacity to meet the growing demands of ... Wilmington site expansion will provide up ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc (NYSE: ... agreement with the New York State ... of the Sherman Act, and other statutes with the Attorney ... February 2014, to cease marketing and selling the now generic ... settlement, Allergan admits no liability, has released its counterclaims against ...
(Date:11/25/2015)... USP 800 applies to all healthcare ... pharmacy technicians, nurses, physicians, physician assistants, home healthcare ... covers all entities which store, prepare, transport, or ... institutions, patient treatment clinics, physicians, practice facilities, and ... --> What is the purpose of USP ...
Breaking Medicine Technology: